ESR1 and invasive breast carcinoma: One hundred seventy-five women who were postmenopausal at diagnosis for stage I–III, HER2-negative, invasive breast cancer with HSD3B1 genotype were ultimately included in analyses, including 129 with ER-positive and 46 with ER-negative tumors; a flow diagram is shown in Figure 2.